We Still Can't Ignore Long Covid... Dr. Jeffrey Cleland, CEO Ashvattha Therapeutics

In this week's episode of Biotech Nation, Dr. Jeffrey Cleland, the President and CEO of Ashvattha Therapeutics, discusses their drug development efforts to address long COVID. They discuss the definition of long COVID by the World Health Organization, the prevalence of the condition, and the chronic inflammation that occurs in the body, including the brain. Dr. Cleland explains how their nanomedicine approach aims to selectively target and turn off reactive inflammatory cells, potentially offering a treatment for long haul COVID and other diseases.